Literature DB >> 8657213

Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients.

J Kurtzberg1, M Laughlin, M L Graham, C Smith, J F Olson, E C Halperin, G Ciocci, C Carrier, C E Stevens, P Rubinstein.   

Abstract

BACKGROUND: Transplantation of bone marrow from unrelated donors is limited by a lack of HLA-matched donors and the risk of graft-versus-host disease (GVHD). Placental blood from sibling donors can reconstitute hematopoiesis. We report preliminary results of transplantation using partially HLA-mismatched placental blood from unrelated donors.
METHODS: Twenty-five consecutive patients, primarily children, with a variety of malignant and non-malignant conditions received placental blood from unrelated donors and were evaluated for hematologic and immunologic reconstitution and GVHD. HLA matching was performed before transplantation by serologic typing for class I HLA antigens and low-resolution molecular typing for class II HLA alleles. In donor-recipient pairs who differed by no more than one HLA antigen or allele, high-resolution class II HLA typing was done retrospectively. Fordonor-recipient pairs who were mismatched for two HLA antigens or alleles, high-resolution typing was used prospectively to select the best match for HLA-DRB1.
RESULTS: Twenty-four of the 25 donor-recipient pairs were discordant for one to three HLA antigens. In 23 of the 25 transplant recipients, the infused hematopoletic stem cells engrafted. Acute grade III GVHD occurred in 2 of the 21 patients who could be evaluated, and 2 patients had chronic GVHD. In vitro proliferative responses of T cells and B cells to plant mitogens were detected 60 days after transplantation. With a median follow-up of 12 1/2 months and a minimal follow-up of 100 days, the overall 100-day survival rate among these patients was 64 percent, and the overall event-free survival was 48 percent.
CONCLUSIONS: HLA-mismatched placental blood from unrelated donors is an alternative source of stem cells for hematopoietic reconstitution in children.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8657213     DOI: 10.1056/NEJM199607183350303

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  136 in total

1.  Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization.

Authors:  T Murohara; H Ikeda; J Duan; S Shintani; K i Sasaki; H Eguchi; I Onitsuka; K Matsui; T Imaizumi
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  Hematopoietic stem cell transplantation: current status of old issues.

Authors:  N Kapoor
Journal:  J Clin Immunol       Date:  2001-11       Impact factor: 8.317

Review 3.  Hematopoietic stem cell transplantation for severe combined immune deficiency.

Authors:  K I Weinberg; N Kapoor; A J Shah; G M Crooks; D B Kohn; R Parkman
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

Review 4.  Umbilical cord blood transplantation.

Authors:  A M Will
Journal:  Arch Dis Child       Date:  1999-01       Impact factor: 3.791

Review 5.  Diamond-Blackfan Anaemia: an overview.

Authors:  I Dianzani; E Garelli; U Ramenghi
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

6.  Knowledge and attitudes of pregnant women with regard to collection, testing and banking of cord blood stem cells.

Authors:  Conrad V Fernandez; Kevin Gordon; Michiel Van den Hof; Shaureen Taweel; Françoise Baylis
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

Review 7.  Hematopoietic stem cell transplantation: a primer for the primary care physician.

Authors:  Chantal S Léger; Thomas J Nevill
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

8.  Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Authors:  Junya Kanda; David A Rizzieri; Cristina Gasparetto; Gwynn D Long; John P Chute; Keith M Sullivan; Ashley Morris; Clayton A Smith; Donna E Hogge; Janet Nitta; Kevin Song; Donna Niedzwiecki; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-22       Impact factor: 5.742

9.  Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice.

Authors:  Simon N Robinson; Paul J Simmons; Michael W Thomas; Nathalie Brouard; Jeannie A Javni; Suprita Trilok; Jae-Seung Shim; Hong Yang; David Steiner; William K Decker; Dongxia Xing; Leonard D Shultz; Barbara Savoldo; Gianpietro Dotti; Catherine M Bollard; Leonard Miller; Richard E Champlin; Elizabeth J Shpall; Patrick A Zweidler-McKay
Journal:  Exp Hematol       Date:  2012-02-02       Impact factor: 3.084

10.  Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors.

Authors:  Margaret L MacMillan; Daniel J Weisdorf; Claudio G Brunstein; Qing Cao; Todd E DeFor; Michael R Verneris; Bruce R Blazar; John E Wagner
Journal:  Blood       Date:  2008-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.